Charles River Laboratories and Magellan Stem Cells announced a collaboration on Oct. 13, 2026, bringing cGMP next-generation sequencing viral safety testing to Zelestrocel, Magellan’s off-the-shelf osteoarthritis stem cell therapy candidate.
AbbVie has presented detailed Phase 1 data for ABBV-295 at EASD 2026, demonstrating meaningful body weight reduction, favorable tolerability and an approximately 11–12-day half-life. The investigational long-acting amylin analog is advancing toward Phase 2 development for chronic weight management, with potential dosing intervals extending beyond weekly administration.
Johnson & Johnson announces 89% complete response rate with Erda-iDRS for intermediate-risk non-muscle-invasive bladder cancer. First-in-human trial shows durable 18-month responses with tolerable safety profile.
Eyestem’s new cell therapy for Dry AMD, showing promising safety and vision improvement in Phase 1 trials. A new hope for treating geographic atrophy.
The stepwise vaccination approach successfully activated and matured B cells toward producing broadly neutralizing antibodies, marking a major milestone in the pursuit of an effective HIV vaccine.
For the clinical phase, Bayer has acquired the sole global license for an MTA-cooperative PRMT5 inhibitor that targets MTAP-deleted tumors selectively.
